Brain MRF for Acute Leukemia
Trial Summary
What is the purpose of this trial?
The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing there. Studies in these cancer survivors have shown that the exposure to these chemotherapy drugs can lead to risks for impaired brain function, also referred to as neurocognitive side effects of chemotherapy. There is an opportunity to identify participants at risk for these side effects and to prevent their development. The purpose of this study is to incorporate a brain imaging tool known as Magnetic Resonance Fingerprinting (MRF) to look for brain matter changes in acute leukemia participants receiving chemotherapy. The MRF scan will be performed at diagnosis and repeated at multiple times during the entire therapy duration as well as at defined intervals after therapy is complete. Investigators would also do an electronic test of memory and brain function (cognitive function), which would be administered in a gaming format on iPads or a similar device. The goal will be to correlate results of MRF imaging with the tests of cognitive function. The benefits of this imaging technique include that it can be done quickly (in minutes), it is non-invasive, it is resistant to motion-artifacts and it can be easily repeated for comparison purposes. The advantages of the cognitive test include its short duration of 20 minutes and its gaming format making it friendly for children to use.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is Brain MRF for Acute Leukemia safe for humans?
The safety data for treatments similar to Brain MRF, like chemotherapy for leukemia, show that there can be effects on the brain, such as changes in brain connectivity and cognitive functions. These effects have been observed in treatments for leukemia, but specific safety data for Brain MRF itself is not available.12345
How is the Brain MRF treatment for acute leukemia different from other treatments?
The Brain MRF treatment for acute leukemia is unique because it focuses on neurocognitive studies, which means it looks at how the treatment affects brain function and thinking skills. This is different from other treatments that may not specifically address or monitor changes in brain function during and after treatment.16789
Research Team
Mari H Dallas, MD
Principal Investigator
University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center
Eligibility Criteria
This trial is for children, adolescents, and young adults with acute leukemia. Participants must be diagnosed with conditions like Acute Lymphoblastic Leukemia or Myeloproliferative Neoplasms. Specific eligibility criteria are not provided but typically include factors like age range, health status, and type of leukemia.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a baseline MRF imaging exam along with neurocognitive testing before starting induction chemotherapy
Treatment
Participants receive chemotherapy with MRF scans every 6 months during therapy
Follow-up
Participants are monitored for brain tissue changes and neurocognitive function every 6 months during the first year of the off-therapy period
Treatment Details
Interventions
- MRF with neurocognitive studies
Find a Clinic Near You
Who Is Running the Clinical Trial?
Case Comprehensive Cancer Center
Lead Sponsor